Pomerantz Law Firm Investigates Bright Minds Bioscience Following FDA Clinical Hold
Pomerantz LLP has launched an investigation into Bright Minds Bioscience Inc. (NASDAQ: DRUG) regarding potential securities fraud or unlawful business practices. The probe follows a significant regulatory setback involving the company's investigational new drug application for BMB-101. On November 2, 2026, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the proposed Phase 2 clinical trial for BMB-101. The FDA cited concerns regarding identified toxicity in mice and insufficient pharmacokinetic and juvenile toxicity data required to support pediatric enrollment. The announcement triggered a severe market reaction, with Bright Minds' stock price plummeting 52.35%, or $28.78 per share, to close at $26.20 on the day of the news.

Tickers: $DRUG
Topics: Class action lawsuit Clinical trial toxicity FDA clinical hold Securities fraud investigation